| Spectinomycin CAS | 22189-32-8 |
|---|---|
| Lincomycin CAS | 859-18-7 |
| Antibiotic Classes | Aminocyclitol (Spectinomycin); Lincosamide (Lincomycin) |
| Category | Veterinary Antibiotics |
| Combination Name | Lincospectin |
| Spectinomycin Regulatory | FDA VMF 005884, CEP 2024-135-REV 00 |
| Lincomycin Regulatory | USP / EP / CEP |
| Primary Applications | Poultry CRD, Swine Dysentery, Bacterial Enteritis |
Spectinomycin and lincomycin are two cornerstone veterinary antibiotics with complementary mechanisms of action. Their fixed-dose combination (Lincospectin) is widely used in poultry and swine for respiratory and enteric infections. For veterinary pharmaceutical buyers, formulators, and regulatory professionals, understanding the differences between these two APIs is essential for making informed sourcing decisions. This comparison covers chemical profiles, activity spectra, clinical applications, regulatory status, and practical supply considerations relevant to the 2026 market.
Spectinomycin is an aminocyclitol antibiotic structurally related to aminoglycosides but with a distinct mechanism of action. Unlike aminoglycosides, spectinomycin does not cause misreading of the genetic code; it binds specifically to the 30S ribosomal subunit and inhibits translocation during protein synthesis. The compound is produced by fermentation of Streptomyces spectabilis. Spectinomycin hydrochloride (HCl) is the most common pharmaceutical salt form used in veterinary formulations, with the molecular formula C14H24N2O7 - HCl - 5H2O and CAS number 22189-32-8. It is a white to off-white crystalline powder, freely soluble in water, and stable under normal storage conditions at controlled room temperature (15--25 degrees C). The pH of a 10% aqueous solution typically falls in the range of 3.8--5.6.
Spectinomycin is primarily bacteriostatic at therapeutic concentrations, though bactericidal activity can be achieved against highly susceptible organisms at elevated concentrations. According to the DrugBank entry (DB00919), spectinomycin's selective binding to the 30S ribosomal subunit distinguishes it from other aminocyclitols and contributes to its favorable safety profile in target animal species.
Lincomycin is a lincosamide antibiotic produced by fermentation of Streptomyces lincolnensis. It binds to the 50S ribosomal subunit and inhibits peptide bond formation during the early stages of protein synthesis. The hydrochloride salt (lincomycin HCl) is the standard pharmaceutical form for veterinary APIs, with the molecular formula C18H34N2O6S - HCl - H2O and CAS number 859-18-7. Lincomycin HCl appears as a white or almost white crystalline powder, freely soluble in water and slightly soluble in ethanol. A 10% aqueous solution has a pH range of 3.0--5.5.
Lincomycin is primarily bacteriostatic against susceptible organisms. It shows particularly strong activity against Gram-positive bacteria and obligate anaerobes, a pattern that largely complements spectinomycin's Gram-negative spectrum. The DrugBank entry (DB01627) documents lincomycin's binding to the 23S rRNA of the 50S subunit, blocking peptide bond formation by interfering with both A-site and P-site tRNA positioning.
Spectinomycin targets the 30S ribosomal subunit while lincomycin targets the 50S subunit. This mechanistic difference is the foundation of their synergistic activity when used in combination: simultaneous binding to two distinct ribosomal targets reduces the probability of resistance emergence and broadens the antibacterial spectrum beyond what either compound achieves alone. Spectinomycin shows primary activity against Gram-negative organisms and mycoplasmas, whereas lincomycin is predominantly active against Gram-positive cocci and bacilli as well as obligate anaerobes. Their pharmacokinetic profiles also differ meaningfully: spectinomycin achieves high tissue concentrations rapidly after parenteral administration, while lincomycin demonstrates excellent penetration into bone, joints, and respiratory tissues.
Spectinomycin demonstrates clinically useful activity against a range of Gram-negative bacteria including Escherichia coli, Salmonella spp., Pasteurella multocida, and Haemophilus spp. Its activity against mycoplasmas is particularly important in veterinary medicine: Mycoplasma gallisepticum and Mycoplasma synoviae, the primary causative agents of chronic respiratory disease (CRD) in poultry, are susceptible to spectinomycin. This mycoplasma activity makes spectinomycin a first-line component in CRD treatment protocols across the global poultry industry. The compound is less active against most Gram-positive cocci and has negligible activity against obligate anaerobes, which represents its primary clinical limitation when used as monotherapy.
Lincomycin's antibacterial spectrum is dominated by Gram-positive organisms: Staphylococcus spp. (including penicillinase-producing strains), Streptococcus spp., Clostridium spp., and other Gram-positive pathogens. Its activity against obligate anaerobes is clinically significant, including Bacteroides spp. and Fusobacterium spp. This anaerobic coverage is particularly relevant in swine enteric disease, where mixed infections involving anaerobic bacteria are common. Lincomycin also shows activity against Mycoplasma spp., though typically at higher MIC values than spectinomycin. Lincomycin is not active against most aerobic Gram-negative enteric bacteria, making it ineffective as monotherapy for colibacillosis or salmonellosis.
The combination of spectinomycin and lincomycin at a typical 2:1 ratio (spectinomycin:lincomycin) creates a broad-spectrum antibacterial profile covering Gram-negative bacteria, Gram-positive bacteria, mycoplasmas, and anaerobes. Published veterinary pharmacology literature confirms that this combination achieves activity against the major bacterial pathogens encountered in poultry and swine respiratory and enteric disease complexes. The complementary spectrum is the primary reason Lincospectin formulations are among the most widely prescribed veterinary antibiotics for mixed infections where the causative organisms have not been definitively identified through culture and sensitivity testing.
Chronic Respiratory Disease (CRD) in poultry, primarily caused by Mycoplasma gallisepticum with secondary bacterial involvement from E. coli and Pasteurella spp., is one of the most economically significant diseases in commercial poultry production worldwide. Spectinomycin provides direct antimycoplasmal activity, while lincomycin addresses secondary Gram-positive and anaerobic organisms. The combined Lincospectin formulation administered via drinking water or parenteral injection has demonstrated efficacy in reducing mortality, improving weight gain, and lowering lesion scores in controlled field studies. According to WOAH (World Organisation for Animal Health) guidelines, spectinomycin-lincomycin combination is a recognized therapeutic option in poultry CRD treatment protocols.
Swine dysentery, caused by Brachyspira hyodysenteriae, and porcine proliferative enteropathy (ileitis), caused by Lawsonia intracellularis, are major enteric diseases in commercial swine production. Lincomycin has well-documented efficacy against both pathogens and has been a standard treatment for swine dysentery for decades. The addition of spectinomycin broadens coverage to include Gram-negative enteric organisms such as Salmonella and E. coli that frequently complicate swine enteric disease, especially in post-weaning and grower-finisher pigs. The combination is typically administered via feed or drinking water at therapeutic doses for 5--7 consecutive days.
Published veterinary clinical studies have demonstrated that the spectinomycin-lincomycin combination achieves clinical cure rates comparable to or exceeding those of alternative antibiotic regimens (including enrofloxacin, tilmicosin, and tiamulin) for specific indications. For poultry CRD, meta-analyses of field trials indicate that Lincospectin treatment reduces mortality by 40--60% compared with untreated controls and improves feed conversion ratios. For swine dysentery, lincomycin-based regimens achieve clinical cure rates exceeding 80% when treatment is initiated early. The combination formulation consistently demonstrates efficacy advantages over spectinomycin or lincomycin monotherapy in cases where mixed infections are suspected, which represents the majority of field presentations.
Spectinomycin is poorly absorbed from the gastrointestinal tract when administered orally, which is why parenteral (intramuscular or subcutaneous) administration is the preferred route for systemic infections in poultry and swine. Following intramuscular injection, peak plasma concentrations are achieved within 0.5--1 hour, and the elimination half-life ranges from 1--2 hours in most veterinary species. Spectinomycin distributes widely into body tissues including the respiratory tract, achieving lung-to-plasma concentration ratios greater than 1. The compound is excreted primarily unchanged in the urine via glomerular filtration.
Lincomycin is better absorbed after oral administration than spectinomycin, with bioavailability values of approximately 30--40% in swine and lower in poultry. Intramuscular administration yields near-complete bioavailability. Lincomycin demonstrates superior tissue penetration compared with spectinomycin, particularly into bone, joint spaces, and the respiratory tract. The elimination half-life is approximately 3--6 hours in swine and 2--4 hours in poultry. Lincomycin undergoes partial hepatic metabolism, with both parent compound and metabolites excreted in urine and bile.
Withdrawal periods vary by jurisdiction and formulation. For poultry, typical withdrawal periods for spectinomycin-lincomycin combination products range from 5--7 days for meat and eggs depending on the specific product registration and the target market's MRL (Maximum Residue Limit) requirements. Swine withdrawal periods are generally in the range of 2--5 days for meat. Buyers formulating finished veterinary products must verify withdrawal period requirements with the regulatory authority in the target registration market.
The term "Lincospectin" refers to the fixed-dose combination of lincomycin (one part) and spectinomycin (two parts) that has been commercially available as a veterinary formulation since the 1970s. The combination delivers three clinically meaningful advantages over either API used alone:
Broader antibacterial spectrum: The Gram-negative and mycoplasma coverage of spectinomycin combined with the Gram-positive and anaerobic coverage of lincomycin creates an antibacterial spectrum that covers the major pathogens involved in poultry respiratory disease complex and swine enteric disease complex.
Reduced resistance emergence: Simultaneous targeting of two distinct ribosomal binding sites (30S for spectinomycin, 50S for lincomycin) means that a single-step bacterial mutation is unlikely to confer resistance to both compounds. This mechanistic rationale is supported by in vitro mutant selection studies showing that the frequency of resistance to the combination is orders of magnitude lower than the frequency of resistance to either compound alone.
Clinical convenience: A single combination product replaces two separate antibiotic preparations, simplifying veterinary prescribing, pharmacy inventory, and administration protocols. This convenience factor is significant in large-scale poultry and swine operations where treatment must be administered to thousands of animals efficiently.
Spectinomycin HCl API is supported by regulatory filings that facilitate dossier submission in multiple markets. The US FDA Veterinary Master File (VMF) 005884 provides confidential detailed information about the manufacturing facility, process, and quality controls for spectinomycin HCl to support ANDA/NADA submissions for veterinary drug products in the United States. The CEP (Certificate of Suitability) 2024-135-REV 00, issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), confirms that the spectinomycin HCl manufacturing process and quality comply with the relevant European Pharmacopoeia monograph. A valid CEP is the most efficient route for demonstrating API quality in EU marketing authorization applications.
Lincomycin HCl API is manufactured to meet USP (United States Pharmacopeia) and EP (European Pharmacopoeia) monograph specifications. A CEP is available for lincomycin HCl from qualified manufacturers, providing the same regulatory efficiency advantages for EU dossier submission. The USP monograph specifies assay limits (not less than 790 microgram/mg on the anhydrous basis for lincomycin), identification tests (HPLC, IR), pH, water content, and related substances limits that form the core of the quality specification.
For veterinary pharmaceutical companies preparing regulatory submissions, the availability of both VMF and CEP documentation for spectinomycin and CEP documentation for lincomycin notably reduces the API-related data requirements in the dossier. For further information on regulatory terminology, see the KingWish Glossary entries on VMF, CEP, and GMP.
Spectinomycin HCl and lincomycin HCl are both fermentation-derived APIs, and their pricing is influenced by fermentation capacity, raw material costs (fermentation media components), and the competitive landscape of Chinese veterinary antibiotic manufacturers. Spectinomycin HCl typically trades at a moderate premium to lincomycin HCl on a per-kilogram basis due to the relative complexity of the fermentation and purification process. Typical MOQ (Minimum Order Quantity) for spectinomycin HCl is 25--50 kg, while lincomycin HCl MOQ is commonly 25--100 kg depending on the supplier and grade.
Standard packaging for both APIs is 25 kg per fiber drum with double-layer PE liner. Both products are stable at ambient temperature (15--25 degrees C) and do not require cold chain logistics. Lead times from Chinese manufacturers range from 4--8 weeks for stock availability; production orders without stock may require 8--12 weeks plus logistics transit time. Combined orders of both APIs from a single supplier can reduce per-kilogram logistics costs through consolidated shipping and simplified documentation handling compared with sourcing from two separate suppliers.
If the primary disease target involves Gram-negative bacteria or mycoplasmas (poultry CRD, colibacillosis), spectinomycin should form the foundation of the formulation. If the primary target is Gram-positive pathogens or anaerobes (swine dysentery, clostridial enteritis), lincomycin is the appropriate primary API selection. For mixed infections or broad-spectrum empirical therapy where precise pathogen identification is not available, the Lincospectin combination is the evidence-based choice.
Formulators developing new veterinary antibiotic products must decide whether to register a single-API product (spectinomycin or lincomycin monotherapy) or a combination product (Lincospectin). Single-API products have simpler regulatory pathways, shorter development timelines, and lower API procurement costs. Combination products offer broader clinical utility, stronger differentiation in competitive markets, and the potential for premium pricing. The combination route is generally preferred for mature markets where differentiation through clinical spectrum is valued by veterinarians.
When selecting an API supplier, the availability of regulatory filing support is a critical criterion. Both spectinomycin HCl and lincomycin HCl from KingWish are supported by comprehensive technical packages including Drug Master Files, Certificates of Suitability, GMP certificates, and stability data. The supplier's ability to provide a Letter of Authorization (LoA) for cross-referencing the VMF or CEP in the buyer's regulatory dossier is essential for efficient marketing authorization submission. Suppliers that cannot provide an LoA or adequate CMC (Chemistry, Manufacturing and Controls) documentation add significant cost and delay to the registration process.
KingWish supplies spectinomycin HCl API manufactured under GMP conditions with full regulatory documentation including US FDA Veterinary Master File (VMF 005884) and CEP 2024-135-REV 00. The product meets current pharmacopoeia specifications with batch-to-batch consistency verified through comprehensive quality control testing. Available packaging is standard 25 kg fiber drums. Custom packaging specifications can be accommodated upon request. The complete regulatory dossier including open part DMF, CEP, GMP certificate, CoA template, and MSDS is available to qualified buyers. For detailed product specifications, see Spectinomycin HCl Product Page.
KingWish supplies lincomycin HCl API manufactured to USP and EP monograph standards, supported by CEP documentation and GMP certification. The product is available in standard 25 kg fiber drum packaging, with batch-specific Certificates of Analysis provided before shipment. The technical package includes the open part of the CEP dossier, GMP certificate, CoA template, MSDS, and stability data. For detailed product specifications, see Lincomycin HCl Product Page.
Sourcing both spectinomycin HCl and lincomycin HCl from KingWish as a single lincospectin china supplier and china veterinary antibiotic api exporter offers practical advantages for veterinary pharmaceutical buyers. The spectinomycin lincomycin combo api china procurement model consolidates two critical APIs under one quality agreement: consolidated documentation streamlines dossier preparation, combined shipment reduces per-kilogram logistics costs, single-supplier quality agreements simplify supplier management, and consistent batch numbering across both APIs facilitates internal traceability. Buyers developing Lincospectin-type combination products especially benefit from the ability to qualify both APIs from one qualified source.